Get started
Author

Nadine Henderson

Observed names: N Henderson, N. Henderson
Observed institution: Office Of Health Economics
ORCID: 0000-0002-0981-9376
Observed ORCID: 0000-0002-0981-9376
OpenAlex ID: A5010223717
Considering Severity in Health Technology Assessment: Can We Do Better?
2022 · Chris Skedgel, Nadine Henderson, et al. · Value in Health · 52
A qualitative systematic review of the impact of hearing on quality of life
2024 · Nadine Henderson, Sian Hodgson, et al. · Quality of Life Research · 49
PDF
Moving towards a more environmentally sustainable pharmaceutical industry: recommendations for industry and the transition to green HTA
2023 · Isobel Firth, Jake Hitch, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 18
PDF
Resource allocation in public sector programmes: does the value of a life differ between governmental departments?
2023 · Patricia Cubi-Molla, David Mott, et al. · Cost Effectiveness and Resource Allocation · 12
PDF
The impact of higher uptake of plant-based diets in England: model-based estimates of health care resource use and health-related quality of life
2023 · Nadine Henderson, Chris Sampson · medRxiv · 3
PDF
Ethical and Economic Issues in the Appraisal of Medicines for Ultra-Rare Conditions
2020 · Nadine Henderson, María Errea Rodríguez, et al. · 3
OP137 A Qualitative Exploration Of The National Institute For Health And Care Excellence’s Impact On International Health Technology Assessment
2023 · Nadine Henderson, Simon Brassel, et al. · International Journal of Technology Assessment in Health Care · 1
PDF
HPR185 The International Impact of National Institute for Health and Care Excellence (NICE) Decisions
2022 · S Brassel, E Oliver, et al. · Value in Health · 1
PDF
PP106 Twenty Years Of Orphan Medicines Regulation: Have Treatments Reached Patients In Need Across Europe And Canada?
2021 · Nadine Henderson, Phill O'Neill, et al. · International Journal of Technology Assessment in Health Care · 1
PDF
A Case Study Analysis: Challenges in the NICE Evaluation of Multi-Indication Medicines for Rare and Ultra-Rare Diseases
2021 · Nadine Henderson, I. Firth, et al. · 1
HTA1 Adaptive Pathways for Tumour Agnostic Medicines in Various Developed Markets
2020 · M. Rodes Sanchez, N. Henderson, et al. · Value in Health · 1
Capturing the Lived Experiences of Informal Care in Acute Leukaemia: A Multinational Qualitative Study
2026 · Samantha Nier, Claud Theakston, et al. · Patient
PDF
Optimisation or Restriction? Unpacking the Logic Behind NICE Decisions
2026 · Nadine Henderson, Brittany Darrow, et al. · PharmacoEconomics
PDF
PD203 Comparison Of Health Technology Assessment Methodologies Across Australia, Canada, New Zealand And The United Kingdom: Implications For Future Collaboration
2024 · Nadine Henderson, Claud Theakston, et al. · International Journal of Technology Assessment in Health Care
PDF
Experiences and Preferences of Acute Leukemia Caregivers: A Qualitative Study
2024 · Nadine Henderson, Claud Theakston, et al. · Blood
HTA156 Health Technology Assessment of Multiple Myeloma Therapies: Value Demonstration and Value Recognition Challenges
2023 · N. Henderson, M. Neri, et al. · Value in Health
Works count: 16
Citation count: 142
H-index: 4
I10-index: 4
Year
Topic
Type